Comparison of the Safety and Efficacy of Cyclosporine Minimization Versus Cyclosporine Elimination in De Novo Renal Allograft Patients Receiving Sirolimus

Transplantation Proceedings

Volumn 42, Issue 5, 2010, Pages 1659-1666

  Tedesco Silva, H ^a   Garcia, V Duro ^b   Contieri, F L C ^c   De Boni Monteiro de Carvalho, D ^d   Noronha, I L ^e   Goncalves R T ^f   de Paula, F Jota ^g   Abbud Filho, M ^h   Manfro, R C ⁱ   David Neto, E ^g   Alfieri, F ^j   Ikehara, E ^j   Jiang, Q ^k   Tai, S S ^k   Medina Pestana, J O ^a  

^a HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^b Hospital Dom Vicente Scherer   (Brazil)

^c Division of Infectious and Parasitic Diseases Hospital Evangélico de Curitiba   (Brazil)

^d HOSPITAL GERAL DE BONSUCESSO   (Brazil)

^e HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^f Clementino Fraga Filho University Hospital   (Brazil)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h Instituto de Urologia e Nefrologia São José do Rio   (Brazil)

ⁱ HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^j Wyeth Brazil   (Brazil)

^k PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; IMMUNOGLOBULIN; RAPAMYCIN; STEROID;

ABDOMINAL PAIN; ACNE; ACUTE GRAFT REJECTION; ADULT; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; BLOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; HERPES SIMPLEX; HIRSUTISM; HUMAN; HYPERESTHESIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LOADING DRUG DOSE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PERIPHERAL EDEMA; PHASE 4 CLINICAL TRIAL; PNEUMONIA; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; THROMBOCYTOPENIA; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADULT; CADAVER; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; PATIENT SELECTION; SIROLIMUS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77953790902     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.02.083     Document Type: Article

References (10)

1. Kahan B.D., and Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 356 (2000) 194
2. MacDonald A.S., and Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271
3. Gonwa T.A., Hricik D.E., Brinker K., et al., Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74 (2002) 1560
4. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777
5. Kreis H., Oberbauer R., Campistol J.M., et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15 (2004) 809
6. Oberbauer R., Kreis H., Johnson R.W., et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76 (2003) 364
7. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22
8. Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75 (2003) 1404
9. Knight R.J., and Kahan B.D. The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?. Kidney Int 70 (2006) 994
10. Ruiz J.C., Campistol J.M., Sanchez-Fructuoso A., et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplant Proc 39 (2007) 2151